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SUMMARY 
Objectives: We explored the possibility that heme, an inflammatory mediator and 
a product of intravascular hemolysis in patients with hemolytic anemia including sickle 
cell disease, could modulate hemostasis by an effect on endothelial tissue factor (TF) 
expression.  Methods: Levels of TF mRNA, protein, and procoagulant activity were 
measured in heme-treated endothelial cells.  Results: Heme induces TF expression on 
the surface of both macro- and micro-vascular endothelial cells in a concentration-
dependent manner with 12- to 50-fold induction noted (ELISA assays) between 1 and 
100 µM heme (P<0.05).  Complementary flow cytometry studies showed that the heme-
mediated endothelial TF expression was quantitatively similar to that of TNF-α.  Heme 
also up-regulated the expression of TF mRNA (8- to 26-fold), protein (20- to 39-fold) and 
procoagulant activity (5- to 13-fold) in endothelial cells in a time-dependent manner.  
Time-course of heme-mediated TF antigen expression paralleled induction of 
procoagulant activity with antibody blocking studies demonstrating specificity for TF 
protein.  IL-1α, and TNF-α are not involved in mediating the heme effect, since 
antibodies against these cytokines, and IL-1-receptor antagonist failed to block heme-
induced TF expression.  Inhibition of heme-induced TF mRNA expression by 
sulfasalazine and curcumin suggested that the transcription factor NFκB is involved in 
mediating heme-induced TF expression in endothelial cells.  Conclusions: Our results 
demonstrate that heme induces TF expression by directly activating endothelial cells 
and that heme-induced endothelial TF expression may provide a pathophysiologic link 
between the intravascular hemolytic milieu and the hemostatic perturbations previously 
noted in patients with hemolytic anemia including sickle cell disease. 
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INTRODUCTION 
Numerous studies have identified that hemostasis is perturbed in patients with 
hemolytic anemias including sickle cell disease (SCD).  Hemostatic abnormalities 
observed in SCD include evidence for enhanced thrombin generation [1], increased 
circulatory levels of tissue factor (TF) antigen and procoagulant activity [2,3], and 
circulating endothelial cells and endothelial- and monocyte-derived microparticles that 
are positive for TF [4,5].  TF, a cell surface receptor for factor-VII/VIIa, is the physiologic 
initiator of blood coagulation, forming a complex with circulating factor-VIIa, activating 
factor-X with subsequent thrombin generation [6].  Although TF is not constitutively 
expressed on endothelium or monocytes in vivo, its expression can be induced by a 
variety of agonists with pathophysiologic relevance to hemolytic anemias including the 
inflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α), 
hypoxia, shear stress, growth factors, endotoxin and reperfusion injury [7-9].   
Erythrocytes, that undergo hemolysis intravascularly, release heme and 
hemoglobin into the circulation with documented studies suggesting that both heme and 
cell-free hemoglobin may modulate disease severity in patients with SCD by decreasing 
the bio-availability of the cyto-protective mediator nitric oxide (NO) [10-12].  Other 
studies have shown that heme can activate endothelial cells in vitro, up-regulating the 
expression of surface adhesion molecules such as VCAM-1, ICAM-1 and E-selectin 
[13].  Since many cytokine-induced down-stream signaling events in endothelial cells 
are common to both TF induction and adhesion molecule expression, we hypothesized 
that heme could affect hemostasis by modulating endothelial TF expression.  We report 
that heme at pathologically relevant concentrations induces TF mRNA and protein in 
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endothelial cells.  We show that TF produced in response to heme is expressed on the 
cell surface, and that it is functional.   
 
MATERIALS and METHODS 
Materials: Three TF-specific antibodies including a rabbit polyclonal and two mouse 
monoclonal (clones hTF-1 and TF9-10H10) antibodies were used in this study.  The 
rabbit polyclonal antibody and the mouse monoclonal antibody hTF-1 were kindly 
provided by Dr Ronald Bach (VA Medical Center, Minneapolis, MN), and the clone TF9-
10H10 was obtained from Calbiochem (La Jolla, CA).  Details of these antibodies and 
other reagents used are described in the Supplementary Section.   
Culture of Endothelial Cells and THP-1 Cells:  Human umbilical vein endothelial 
cells (HUVECs) were obtained from Clonetics (Lonza, Walkersville, MD) and cultured 
according to the manufacturer’s protocol.  Cells at passages 2 to 4 were used.  All 
experiments were performed using endothelial growth medium containing 50µg/ml 
polymyxin-B (EGM-polyB), unless otherwise indicated.  Representative experiments also 
were performed using human lung microvascular endothelial cells (HLMECs, passages 2 
to 4) from Clonetics.  Endothelial cells were incubated in the absence or presence of the 
desired agonist (1-100µM heme, 10ng/ml IL-1α, or 10ng/ml TNF-α) for various times 
(0.5-8 hours), and then analyzed for TF mRNA, TF protein or TF procoagulant activity.  
As a positive control for inducible TF expression, we used THP-1 cells (a human 
monocytic leukemia cell line, ATCC, Manassas, VA), activated with LPS in the absence of 
polymyxin-B.  
 6 
Preparation of Heme:  Fresh working stocks of 10mM heme were prepared in 
0.05N NaOH, diluted to desired concentration in EGM-polyB, and pH adjusted to 7.4.  
Endotoxin-free water was used in the preparation of all reagents.  Endotoxin levels in 
reagents and media were assessed using a limulus assay kit (Lonza, Wakersville, MD).  
Analysis of Endothelial TF Protein:  Cell surface TF expression was assessed 
using two complementary methods including an ELISA-based assay (intact cell 
monolayer) and flow cytometry (cell suspension) as previously described for endothelial 
adhesion receptors [14].  Total TF protein level was assessed using Western blotting of 
cellular proteins.  While the monoclonal anti-TF antibodies, TF9-10H10 and hTF-1, were 
used in ELISA and/or flow cytometry procedures, the rabbit polyclonal anti-TF antibody 
was employed in Western analysis (for details refer to supplementary section).   
Analysis of Endothelial TF mRNA:  TF mRNA levels in control and treated 
endothelial cultures were measured using a two-step semi-quantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR) assay employing the primers 5’-
TGT-GAC-CGT-AGA-AGA-TGA-ACG-GAC-3’ (forward) and 5’-CCA-CTC-CTG-CCT-
TTC-TAC-ACT-TGT-3’ (reverse), which yielded a 380-bp PCR product for TF.  Identity 
of PCR fragment from the endothelial TF transcript was confirmed by sequencing the 
purified PCR fragment, and matching the sequence with published TF mRNA (for 
details refer to supplementary section).   
TF Functional Activity:  TF procoagulant activity on intact endothelial monolayers 
or in cell lysates prepared from control and treated cultures were measured using a TF 
activity assay kit (American Diagnostica, Stanford, CT).  To confirm that the conversion 
of factor-X to factor-Xa was TF-mediated, in parallel experiments either the cell 
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monolayers (~50,000 cells) or endothelial lysates (2.5µg protein) were pre-incubated 
with the monoclonal anti-TF antibody hTF-1 (15µg) for 30-minutes, and assayed for TF 
activity.     
Statistical analysis: Statistical evaluation was performed using Sigmastat (Jandel, 
San Rafael, CA).  All values presented are mean±SD.  Multiple group comparison was 
done using either one-way ANOVA or the Kruskal-Wallis test, as appropriate, and if 
significant, group-wise comparisons were performed with the Bonferroni or the Dunn’s 
test.  Differences at P<0.05 were considered statistically significant. Paired-group 
comparison was performed using either the paired t-test, or the Mann-Whitney rank sum 
test, as appropriate.     
 
RESULTS 
Effects of Heme on Endothelial Surface TF Antigen Expression:  Using flow 
cytometry and ELISA-based assays, we investigated whether heme induced endothelial 
surface TF expression.  As depicted in Figure-1A, heme up-regulated TF expression on 
intact HUVECs in a concentration-dependent manner with 12-, 20-, and 50-fold 
induction noted at 1, 10, and 100µM heme, respectively, compared to media controls as 
assessed by ELISA.  The effects noted at all heme concentrations were statistically 
significant at P<0.05 or <0.01.  A similar concentration-dependent effect of heme on TF 
expression also was noted on micro-vascular endothelial cells using HLMECs as a 
representative cell system (Figure-1B).  In parallel experiments, the positive control 
TNF-α increased TF expression by ~80-fold on both macro- and micro-vascular 
endothelial cells.  Cell surface TF expression was also confirmed using complementary 
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flow cytometry employing two different monoclonal anti-TF antibodies: TF9-10H10 
(Figure-1C) and hTF-1 (Figure-1D).  Results demonstrate that significant numbers of 
cells acquired TF-positivity following activation with heme (22% and 21% cells with TF9-
10H10 and hTF-1, respectively).  Cells stimulated with the positive control, TNF-α 
exhibited 27% and 26% TF-positivity, respectively.    
Effects of Heme on Endothelial TF mRNA Expression:  In preliminary 
experiments we found that heme induced TF mRNA expression in a concentration-
dependent manner with 8-, 15-, and 26-fold up-regulation noted at 1, 10 and 100µM 
heme, respectively.  Since maximal responses with heme on both TF mRNA and TF 
protein expression (Figure-1) were found at 100µM, our subsequent experiments were 
performed using 100µM heme.  This agonist induced TF mRNA expression in a time-
dependent manner with maximal responses between 2 and 3 hours (Figure-2A).  TF 
induction in response to the positive controls IL-1α and TNF-α occurred earlier when 
compared to heme with TF mRNA already present in endothelial cells within 30-minutes 
following cytokine exposure.  Profiles of TF mRNA expression in endothelial cells and 
THP-1 cells are shown in Figure-2B.  Results demonstrate that total RNA from activated 
endothelial cells and THP-1 cells contained TF mRNA yielding an RT-PCR fragment of 
380-bp.  Identity of the endothelial PCR fragment was confirmed by DNA sequence 
analysis which showed 100% identity to the published TF mRNA sequence.  
Densitometric analyses demonstrated that incubation of endothelial cells with 100µM 
heme for 2-hours up-regulated TF mRNA levels by approximately 17-fold (n=4) 
compared to un-stimulated control cells (Figure-2B), while increases of 29-fold and 48-
fold were noted in cells incubated with TNF-α, and IL-1α, respectively (Figure-2B).  
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Effects of polymyxin-B on LPS-, heme-, and IL-1α-induced endothelial TF expression 
were evaluated.  While polymyxin-B had no inhibitory effect on either heme-, or IL-1α-
induced endothelial TF expression, LPS (1µg/ml)-induced TF mRNA expression was 
inhibited by 86% (supplementary Figure-S1).  In addition, heme used in our experiments 
was free of any detectable endotoxin as assessed by the limulus assay (<0.01EU/ml in 
test medium containing 100µM heme).    
Effects of Heme on Endothelial total TF Protein Levels:   Heme induced TF 
protein expression in a time-dependent manner with 20- to 39-fold stimulation over 
controls noted between 4 and 7 hours with a peak response at 4-hours similar to that 
noted with cytokines. The latter agonists, however, induced significant protein 
expression by 2-hours (Figure-2C).  Western blots from representative experiments 
showing the profiles of TF protein and β-tubulin (the loading control) from endothelial 
cells, and THP-1 cells are shown in Figure-2D.  Results demonstrate that only activated 
endothelial cells and THP-1 cells expressed TF protein.  Densitometric analyses of the 
blots demonstrated that incubation of endothelial cells with 100µM heme for 4-hours up-
regulated TF protein expression by approximately 35-fold (n=4) compared to a 70-fold 
and 88-fold increase in cells incubated with TNF-α, and IL-1α, respectively (Figure-2D).   
Effects of Heme on Endothelial TF Functional Activity:  TF expressed in 
endothelial cells in response to heme (100µM) was functionally active as assessed by 
the ability of cell lysates to convert factor-X to factor-Xa in the presence of exogenously 
provided factor-VIIa.  Heme-treated endothelial cells expressed TF procoagulant activity 
in a time-dependent manner with 5- to 13-fold increases over control between 4 and 7 
hours with peak activity at 4-hours (Figure-3A).  The time-course of TF activity 
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paralleled the time-course of TF antigen expression in heme-treated cells (Figure-3A 
and Figure-2C).  Similar time-course profiles were noted with TNF-α and IL-1α (Figure-
3A).  Blocking experiments with anti-TF (Figure-3B) demonstrated that more than 90% 
of procoagulant activity with all three agonists (heme, TNF-α, and IL-1α)-treated cells 
was specifically TF-associated.  Since TF procoagulant activity in cell lysates measures 
total cellular activity including cell surface, encrypted and intracellular TF, we further 
evaluated whether heme induces the expression of functional procoagulant TF on intact 
endothelium.  Results demonstrate that both heme and cytokines induced cell surface 
TF procoagulant activity with 2.6-, 7.2-, and 11.9-fold increases noted over media 
control (Figure-3C).  Measured surface procoagulant activity was, however <10% of the 
total activity in both heme- and cytokine-activated endothelial cells (Figures-3B and 3C).   
Effects of Curcumin and Sulfasalzine on Heme-Induced TF mRNA Expression:   
In an attempt to assess whether the transcription factor NFκB was involved in mediating 
heme-induced TF expression, we evaluated the effects of inhibitors of NFκB activation 
including sulfasalazine and curcumin [15,16].  Following pretreatment of endothelial 
cells for 30-minutes with sulfasalazine (0.2mM) or curcumin (10µM), monolayers were 
incubated for 2-hours in the absence or presence of 100µM heme.  Results presented in 
Figure-4 demonstrate that both sulfasalazine and curcumin inhibited heme-induced TF 
mRNA expression in endothelial cells suggesting that NFκB is involved in mediating 
heme-induced TF expression.    
DISCUSSION 
We explored the possibility that heme, a product of intravascular hemolysis in 
patients with hemolytic anemias, could modulate hemostasis by an effect on endothelial 
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TF expression.  Our results demonstrate that heme, at pathologically relevant 
concentrations, induces TF expression (both message and protein) in endothelial cells, 
and that it is biologically active.   
TF, a 47-kDa transmembrane glycoprotein, the cellular receptor and cofactor for 
coagulation factor-VII/VIIa, and the predominant initiator of blood coagulation [6], can be 
expressed on activated monocytes and endothelial cells [7].  Expression on the 
endothelium can be induced by a variety of agonists including inflammatory cytokines 
IL-1 and TNF-α [7].  While multiple nuclear transcription factors are involved in TF 
induction in endothelial cells, the agonists IL-1α and TNF-α mediate their effects 
through activation of AP-1 and NFκB [7,17].  Since heme, like IL-1 and TNF-α, appears 
to activate NFκB, inducing the expression of the adhesion molecules ICAM-1, VCAM-1 
and E-selectin on endothelial cells in vitro [13,18], we hypothesized that heme could 
modulate TF expression.  We demonstrate that heme induces expression of both TF 
mRNA and functionally active TF protein with time-courses not too dissimilar to that of 
IL-1α and TNF-α (Figures-2A, 2C and 3A), although the cytokine response occurred 
somewhat earlier.  Further, the heme effect on endothelial TF expression was not 
mediated via release of the endogenous cytokines IL-1α and TNF-α from the test 
endothelial cells (supplementary results). In vitro studies have demonstrated that both 
sulfasalazine and curcumin inhibit NFκB activation in epithelial cells and endothelial 
cells [15,16], and curcumin, in addition, may affect activation of AP-1, Egr-1 and SP-1 
[16].  In preliminary experiments we further assessed whether heme-induced TF 
expression was modulated by sulfasalazine and curcumin.  Both modulators blocked 
heme-induced TF mRNA expression (Figure-4) suggesting that NFκB is one of the 
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transcription factors involved in mediating the observed heme-effects.  In this context it 
is interesting to note that a recent study by Hasan and Schafer has demonstrated that 
induction of Egr-1 expression by heme caused TF expression in vascular smooth 
muscle cells [19].   Using flow cytometry and ELISA, we also show that heme induces 
cell surface expression of TF antigen on both macro-, and micro-vascular endothelial 
cells (Figures-1A and 1B), and that the cell surface expression of TF by heme was 
comparable to that induced by TNF-α (Figures-1C and 1D).  Since plasma heme levels 
in patients with intravascular hemolytic anemia such as SCD and paroxysmal nocturnal 
hemoglobinuria (PNH) have been documented to range between 20µM and 600µM 
[10,20], and since significant changes in TF expression reported here were noted at 
heme concentrations as low as 1µM, the heme-effects observed in our study appear to 
be pathologically relevant.  In addition, relevance may also be extended to situations 
associated with acute elevations in levels of plasma hemoglobin such as 
cardiopulmonary bypass.  These conditions carry an increased thrombotic risk [20-22].   
Since endotoxin can induce TF expression in endothelial cells even at very low 
concentrations, use of endotoxin-free reagents and media in our experiments was 
crucial to delineate the heme-effect.  Previous studies have shown that polymyxin-B 
inhibits endotoxin-induced cell-activation including TF expression in human aortic 
endothelial cells [23].  We have therefore performed all studies in media containing 
polymyxin-B.  In addition, in preliminary experiments we evaluated the effects of 
polymyxin-B on agonist-induced TF expression, and confirmed that this agent blocked 
LPS-mediated, but not heme- or cytokine-induced, TF expression in HUVECs (Figure-
S1).  Moreover, limulus assay on the media used in our studies was noted to be free of 
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any detectable endotoxin.  We further evaluated whether heme (like hemoglobin [24]) 
could potentiate LPS-induced TF expression.  We found no such enhancement 
(supplementary results).  
Although laboratory and clinical evidence demonstrate enhanced thrombin 
generation in patients with hemolytic anemia including SCD, the factor(s) that mediate 
these abnormalities have not been identified.  Our results demonstrate that heme 
induces TF expression at concentrations potentially achievable in the microcirculation.  
Gladwin and coworkers have documented that intravascular hemolysis produces a state 
of resistance to endogenously produced, or exogenously delivered NO, due to the 
stoichiometric oxidation of endogenous NO by cell-free plasma hemoglobin with 
resultant inhibition of vasodilatation [11].  Decreased NO bioavailability, with 
consequential impairment in the salutary effects of NO-induced inhibition of platelet 
aggregation, may be operative in the recently reported enhancement of platelet 
activation in SCD-related pulmonary hypertension [25].  Our findings serve to further 
expand the paradigm of hemolysis-induced NO-dependent endothelial dysfunction to 
additionally include abnormalities in hemostasis based on heme-induced perturbations 
in fluid-phase hemostasis.  In this context it is interesting to note that the study by 
Solovey et al [9] has demonstrated pulmonary endothelial TF expression in sickle 
transgenic mice following experimental reperfusion injury, a model for SCD-related 
vaso-occlusion.  While no studies to date have reported cause and effect relationship 
between intravascular hemolysis and thrombogenic risk in patients with hemolytic 
anemia, a previous preliminary report cited an association between the prothrombotic 
fragment F1.2 and abnormal transcranial Doppler flow velocities in children with SCD 
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[26].  In addition, a recent study by deLatour et al has addressed the thrombotic history 
of 460 patients with PNH [21].  These authors reported episodes of thromboses in 116 
of 454 accessible patients including the Budd-Chiari syndrome, thrombosis of the 
central nervous system, and leg thrombosis suggestive of an association between 
hemolysis and hemostatic perturbations.  Other relevant heme effects reported to date 
include modulation of inflammatory tone by activating neutrophils triggering their 
oxidative burst, and the production of reactive oxygen species [18,27,28].  Our results 
taken together with other heme-related published findings may thus provide a critical 
link between the hemolytic milieu of SCD, coagulation activation and inflammation, and 
further reiterates that interventions aimed at minimizing intravascular hemolysis may 
provide therapeutic benefit.   
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FIGURE LEGENDS 
 
Figure-1:  Effects of Heme and TNF-α on Surface Expression of TF Protein on 
Endothelial Cells: 
Analysis by ELISA.  Following incubation of HUVECs (panel-A) or HLMECs 
(panel-B) for 4-hours in the presence or absence of the indicated concentrations of 
heme or TNF-α, surface TF expression was assessed by ELISA.  Results presented are 
the means±SD from 6 (panel-A) or 3 (panel-B) experiments.  All experiments presented 
were performed with unfixed cells.  We have also performed ELISA assays using fixed 
cells, and found that the TF expression profile in response to activation with heme and 
cytokines was similar to unfixed cell preparations (i.e. increased TF expression in 
activated endothelial cells compared to unstimulated medium control).  An increased 
expression of TF on unstimulated control cells was however noted on un-fixed cells (an 
increase of approximately 20%) compared to fixed cells.  *represents P<0.05 or <0.01 
compared to media control.     
Analysis by Flow Cytometry.  Following incubation of HUVECs for 4-hours in the 
absence (panels-Ci/Di), or presence of 10ng/ml TNF-α (panels-Cii/Dii) or 100µM heme 
(panels-Ciii/Diii), cells were harvested, labeled with anti-TF antibody TF9-10H10 
(panel C) or hTF-1 (panel D), or an equivalent amount of an isotype-matched negative 
immunoglobulin control, and analyzed.  Histogram profiles of FITC-fluorescence from 
cells labeled with anti-TF antibody (gray histogram) and isotype-matched negative 
control (solid black line) are shown.  The positive histogram-region, M1, is defined using 
cells labeled with the isotype control.  Positivity, shown in each panel, is the difference 
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in M1 between the cells labeled with anti-TF and the isotype control.  Results presented 
are from a representative experiment repeated thrice with similar results.  
 
Figure-2:  Effects of Heme and Cytokines on TF mRNA and Protein Levels in 
HUVECs: 
Panel-A: Time-dependent changes in TF mRNA levels: Following incubation of 
HUVECs with the desired agonist (10ng/ml TNF-α, 10ng/ml IL-1α, or 100µM heme) for 
times indicated, total RNA was isolated, and analyzed for TF mRNA by RT-PCR.  The 
experiment was repeated twice with similar results. 
Panel-B: Heme and cytokines up-regulate endothelial TF mRNA expression: 
HUVECs were incubated in the absence (lane-1), or presence of 10ng/ml TNF-α (lane-
2), 10ng/ml IL-1α (lane-3), or 100µM heme (lane-4) for 2-hours, total RNA isolated, and 
then analyzed for TF mRNA.  RT-PCR products of TF mRNA from THP-1 cells (a 
positive control for TF induction) incubated in the absence (lane-5) or presence of 
100ng/ml LPS (lane-6) are shown for comparison.  β-Actin mRNA, a constitutively 
expressing transcript, was co-amplified with TF mRNA as an endogenous control for TF 
mRNA quantitation using previously described primers [14].  The RT-PCR products of 
TF mRNA (380-bp), and β-actin mRNA (687-bp) from a representative gel are shown at 
the top. Band intensities of PCR fragments were determined densitometrically and 
expressed as a ratio of TF to β-actin mRNAs.  Message ratio in the unstimulated 
medium control was 0.26±0.12.  Values (expressed as fold-change compared to media 
control) are the means±SD from four experiments.  *represent P<0.05 compared to 
control.   
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Panel-C: Time-dependent changes in TF protein levels: Following incubation of 
HUVECs with the desired agonist (10ng/ml TNF-α, 10ng/ml IL-1α, or 100µM heme) for 
times indicated, total cellular proteins were isolated, and analyzed for TF protein by 
Western blotting.  The experiment was repeated thrice with similar results.   
Panel-D: Heme and cytokines up-regulate endothelial TF protein expression: 
HUVECs were incubated in the absence (lane-1), or presence of 10ng/ml TNF-α (lane-
2), 10ng/ml IL-1α (lane-3), or 100µM heme (lane-4) for 4-hours and then analyzed for 
TF protein.  Immunoblots from THP-1 cells incubated in the absence (lane-5) or 
presence of 100ng/ml LPS (lane-6) are shown for comparison.  Equal protein loading 
was checked by re-probing the stripped Immunoblots for β-tubulin protein.  TF and β-
tubulin (βT) protein bands from representative immunoblots are shown at the top.  
Intensities of protein bands were determined densitometrically and expressed as a ratio 
between TF and β-tubulin protein. This ratio in the unstimulated medium control was 
0.06±0.06.  Values (expressed as fold-change compared to media control) are the 
means±SD from four experiments.  *represent P<0.05 compared to control.    
 
Figure-3:  Effects of Heme and Cytokines on Endothelial TF Functional Activity:   
Panel-A: Time-Dependent Changes in TF Procoagulant Activity:  Following 
incubation of HUVECs with the desired agonist (10ng/ml TNF-α, 10ng/ml IL-1α, or 
100µM heme) for times indicated, total cellular proteins were extracted and analyzed for 
TF procoagulant activity.  The experiment was repeated thrice with similar results.  
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  Panel-B: Heme and cytokines up-regulate endothelial TF procoagulant activity in 
Cell Lysates:  Following incubation of HUVECs for 4-hours with the desired agonist 
(10ng/ml TNF-α, 10ng/ml IL-1α, or 100µM heme), cell lysates were prepared.  Total 
cellular proteins (2.5µg) were incubated in the presence (black bars) or absence (cross-
hatched bars) of a mouse monoclonal anti-TF antibody (hTF-1, 15µg) for 30-minutes, 
and then assayed for TF functional activity.  Results are the means±SD from five 
experiments.  **P<0.05 or <0.01 compared to media control.  *P<0.005 by paired t-test 
compared to respective no antibody treatment controls.   
Panel-C:  Heme and cytokines up-regulate endothelial TF procoagulant activity on 
Intact Cell Monolayers:  Following activation of HUVECs (~50,000 cells in wells of a 96-
well plate) for 4-hours with the desired agonist (10ng/ml TNF-α, 10ng/ml IL-1α, or 
100µM heme), monolayers were incubated in the presence (black bars) or absence 
(cross-hatched bars) of a mouse monoclonal anti-TF antibody (hTF-1, 15µg) for 30-
minutes, and then assayed for TF functional activity. Results presented are from a 
representative experiment repeated twice with similar results.   
 
Figure-4:  Effects of Sulfasalazine and Curcumin on Heme-Induced Endothelial TF 
mRNA Expression:  
Following pretreatment of HUVECs for 30-minutes with sulfasalazine (0.2mM, 
lane-3) or curcumin (10µM, lane-4), monolayers were incubated for 2-hours in the 
absence (lane-1) or presence of 100µM heme (lanes 2-4).  Total RNA was extracted 
and analyzed for TF mRNA.  β-Actin mRNA was co-amplified with TF mRNA as an 
endogenous control for TF mRNA quantitation.   The RT-PCR products of TF mRNA 
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(380-bp), and β-actin mRNA (687-bp) are shown at the top corner.  Bars represent 
densitometric readings of the ratio between TF and β-actin messages.  Results 
presented are from a representative experiment repeated twice with similar results. 
